Vargatef (nintedanib; Boehringer Ingelheim) is a triple angiokinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), all of which play a central role in the angiogenesis pathway critical for blood vessel formation, facilitating tumor growth and metastasis. VEGF overexpression is typically associated with poor clinical outcomes, and there is evidence that PDGFR and FGFR signaling reduces the efficacy of VEGFR inhibition. Vargatef aims to block tumor growth and development through the inhibition of these angiogenic pathways.
In addition to non-small cell lung cancer, the drug is approved for idiopathic pulmonary fibrosis (branded as Ofev).
4 Drug Overview
5 Product Profiles
5 Vargatef : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
9 Figure 75: Datamonitor Healthcare’s drug assessment summary for cemiplimab in non-small cell lung cancer
12 Figure 76: Cemiplimab sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Vargatef drug profile
7 Table 2: Vargatef pivotal trial data in non-small cell lung cancer
13 Table 3: Vargatef sales for NSCLC across the five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.